A natural protein may protect the GI tract from infection
MIT researchers have discovered that a naturally occurring protein called intelectin-2 both strengthens the gut's protective mucus layer and directly kills dangerous bacteria. This dual-action mechanism could eventually lead to new treatments for antibiotic-resistant infections a...
MIT chemistry professor Laura Kiessling and her team have uncovered a protein already living inside your gut that may be one of the body's most underappreciated weapons against bacterial infection. According to MIT Technology Review's coverage published April 21, 2026, intelectin-2, a lectin protein embedded in the body's mucosal surfaces, can both reinforce the intestinal barrier and directly destroy harmful bacteria, including some of the hardest-to-treat pathogens in clinical medicine.
Why This Matters
Antibiotic resistance is not a future problem. It is killing people right now, and the pipeline for new antibiotics has been nearly dry for decades. A protein that the human body already produces, one that can neutralize Staphylococcus aureus and Klebsiella pneumoniae without relying on conventional antibiotics, represents exactly the kind of biological leverage point researchers have been hunting for. The fact that this protein was sitting in our guts unstudied is both humbling and genuinely exciting for the future of antimicrobial drug development.
Daily briefing from 50+ sources. Free, 5-minute read.
The Full Story
Lectins are proteins embedded in the body's mucosal surfaces, the wet linings of organs like the intestines. Their job, broadly speaking, is to bind to specific sugar molecules on cell surfaces. Researchers have known about lectins for years, but many individual lectin proteins have not received detailed study. Intelectin-2 was one of them, until Kiessling's team at MIT decided to look more closely.
The team found that intelectin-2 targets a sugar molecule called galactose. Galactose shows up in two important places inside the gut: on the outer membranes of bacteria and inside the mucins that form the mucus layer lining the intestine. That dual presence turns out to be the key to understanding why intelectin-2 is so useful.
When intelectin-2 binds to galactose in the mucins, it helps reinforce the physical structure of the mucus layer itself. Think of the mucus lining as a wall. Intelectin-2 acts like mortar, tightening the structure and making it harder for pathogens to punch through. But the real surprise is what happens when bacteria do get through. Intelectin-2 can then bind directly to the galactose on bacterial membranes, trapping the microbes and eventually causing their cell walls to disintegrate. The bacteria, in effect, fall apart.
Kiessling, who conducted the study alongside former MIT postdoc Amanda Dugan and Deepsing Syangtan, who completed his PhD at MIT in 2024, described this two-part action in clear terms. "What's remarkable is that intelectin-2 operates in two complementary ways," Kiessling said. "It helps stabilize the mucus layer, and if that barrier is compromised, it can directly neutralize or restrain bacteria that begin to escape." That is not how most antimicrobial agents work. Most antibiotics do one thing. Intelectin-2 does two.
The clinical implications come into sharper focus when you look at which bacteria it targets. Staphylococcus aureus, which includes the MRSA strain that has become resistant to many common antibiotics, and Klebsiella pneumoniae, a frequent cause of hospital-acquired infections that is increasingly resistant to last-resort treatments, are both in intelectin-2's crosshairs. A natural human protein that can disrupt these pathogens without a pharmaceutical compound is a meaningful finding.
The research also points toward applications in gut disorders. People with inflammatory bowel disease often show abnormal levels of intelectin-2. Too little of the protein may weaken the mucus barrier, leaving the gut exposed. Too much may begin killing off beneficial bacteria, upsetting the delicate microbial balance that keeps the gut healthy. Restoring the protein to appropriate levels could become a therapeutic target for IBD patients, though the research team acknowledges that clinical applications are still years away.
Key Details
- Research led by MIT chemistry professor Laura Kiessling, published and announced in March 2026.
- Co-investigators include Amanda Dugan, a former MIT postdoc and research scientist, and Deepsing Syangtan, PhD class of 2024.
- Intelectin-2 targets galactose, a sugar molecule found on bacterial cell membranes and in gut mucins.
- Bacteria trapped by intelectin-2 eventually disintegrate, suggesting the protein kills by disrupting cell membranes.
- Confirmed effective against at least 2 antibiotic-resistant pathogens: Staphylococcus aureus and Klebsiella pneumoniae.
- Abnormal intelectin-2 levels have been observed in patients with inflammatory bowel disease.
What's Next
Kiessling's team is actively pursuing the idea of harnessing human lectins as antimicrobial agents, using the body's own immune proteins as a template for drug development. The next phases of research will likely focus on understanding dosing, specificity, and how intelectin-2 interacts with beneficial gut bacteria before any clinical trials could begin. Researchers and drug developers working on antibiotic-resistance treatments should be watching this work closely, as it offers a biological mechanism that synthetic compounds have struggled to replicate.
How This Compares
The search for alternatives to conventional antibiotics has produced a range of approaches over the past decade. Phage therapy, which uses viruses to attack specific bacteria, has received considerable attention, with clinical trials in Europe and the United States showing promise against Pseudomonas aeruginosa infections. The intelectin-2 discovery is distinct because it does not introduce a foreign agent. It works with a protein the body already manufactures, which significantly reduces the risk of immune rejection or off-target effects.
Compare this to research on defensins, another class of naturally occurring antimicrobial proteins found in human cells. Defensins have been studied for years as potential drug candidates, with companies like Novabay Pharmaceuticals advancing synthetic defensin mimics through clinical trials. Intelectin-2 is different in that it also performs a structural role in the gut barrier, making it a more complex and potentially more valuable therapeutic target than defensins alone.
There is also relevant context in the growing field of mucosal immunology. Research published in the journal Immunity in late 2023 identified several other mucosal proteins that regulate gut bacteria populations, but none of the identified proteins demonstrated the dual reinforcement-and-kill mechanism that intelectin-2 appears to have. That combination is what makes this MIT finding stand out from adjacent work. For anyone tracking related AI and biotech news, the intersection of machine learning tools and protein discovery is also worth watching, as computational protein-folding tools like AlphaFold 3 have accelerated exactly this kind of structural biology research.
FAQ
Q: What is intelectin-2 and where does it come from? A: Intelectin-2 is a naturally occurring protein embedded in the mucous membranes lining the human gastrointestinal tract. It belongs to a family of proteins called lectins, which bind to sugar molecules on cell surfaces. Your body already produces it as part of its innate immune system, though researchers are only now understanding the full range of what it does.
Q: How does intelectin-2 kill bacteria without antibiotics? A: Intelectin-2 binds to a sugar called galactose found on the outer membranes of certain harmful bacteria. Once bound, it traps the bacteria and disrupts their cell membranes, causing them to break apart and die. This mechanism does not rely on any synthetic compound, meaning bacteria cannot develop resistance to it the same way they do to conventional antibiotics.
Q: Could this become a treatment for inflammatory bowel disease? A: Possibly, but not immediately. Researchers found that IBD patients often have abnormal intelectin-2 levels, either too low or too high, which may contribute to gut barrier problems or disrupted microbiomes. Restoring healthy levels could be a therapeutic goal, but clinical applications would require extensive additional research, including trials to confirm safety and effectiveness in human patients.
The MIT team's discovery is a reminder that the human body is still revealing defenses we have not fully mapped. As antibiotic resistance pushes medicine toward biological alternatives, proteins like intelectin-2 offer a genuinely promising direction, one built from the body's own architecture rather than from scratch. Subscribe to the AI Agents Daily weekly newsletter for daily updates on AI agents, tools, and automation.
Get stories like this daily
Free briefing. Curated from 50+ sources. 5-minute read every morning.
